Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies

详细信息    查看全文

• 作者：Tara Spence^a ; Raquel De Souza^a ; Yannan Dou^a ; Shawn Stapleton^b ; Raymond M. Reilly^a ; ^c ; Christine Allen^a ; ^{cj.allen@utoronto.ca" class="auth_mail" title="E-mail the corresponding author}
• 关键词：18F-FAZA ; 18F-labeled fluoroazomycin arabinoside ; 18F-FDG ; 18F-labeled fluorodeoxyglucose ; 18F-FLT ; 18F-labeled fluorothymidine ; 18F-HX4 ; 18F-labeled flortanidazole ; 18F-MISO ; 18F-labeled fluoromisonidazole ; 62Cu-ATSM ; 62Cu-labeled diacetyl-bis(N-methylthiosemicarbazone) ; ALT ; alanine transaminase ; ATP ; adenosine triphosphate ; BOLD-MRI ; blood oxygenation level dependent magnetic resonance imaging ; CEUS ; contrast-enhanced ultrasound ; CT ; computed tomography ; DCE-MRI ; dynamic contrast enhanced mag
• 刊名：Journal of Controlled Release
• 出版年：2015
• 出版时间：10 December 2015
• 年：2015
• 卷：219
• 期：Complete
• 页码：295-312
• 全文大小：1321 K

文摘

Functional and molecular imaging has become increasingly used to evaluate interpatient and intrapatient tumor heterogeneity. Imaging allows for assessment of microenvironment parameters including tumor hypoxia, perfusion and proliferation, as well as tumor metabolism and the intratumoral distribution of specific molecular markers. Imaging information may be used to stratify patients for targeted therapies, and to define patient populations that may benefit from alternative therapeutic approaches. It also provides a method for non-invasive monitoring of treatment response at earlier time-points than traditional cues, such as tumor shrinkage. Further, companion diagnostic imaging techniques are becoming progressively more important for development and clinical implementation of targeted therapies. Imaging-based companion diagnostics are likely to be essential for the validation and FDA approval of targeted nanotherapies and macromolecular medicines. This review describes recent clinical advances in the use of functional and molecular imaging to evaluate the tumor microenvironment. Additionally, this article focuses on image-based assessment of distribution and anti-tumor effect of nano- and macromolecular systems.